Targeted therapy for metastatic renal cell cancer.
Renal cell cancer is a common urological malignancy for which the incidence has doubled over the last three decades. Thirty percent of patients have metastatic disease at the moment of diagnosis. Thirty percent of the remaining surgically treated patients will develop metastases. Before the introduction of targeted therapies the only therapeutic option for these patients was immunotherapy with bad tolerability and poor results. This review discusses these new 'targeted therapies'.
Verbaeys
C
C
Ghent University Hospital, Department of Urology, Belgium.
Hoebeke
P
P
Van Belle
S
S
Rottey
S
S
D000970:Antineoplastic Agents / Q000627:therapeutic use; D002292:Carcinoma, Renal Cell / Q000556:secondary* / Q000628:therapy*; D003131:Combined Modality Therapy; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use; D007680:Kidney Neoplasms / Q000473:pathology* / Q000628:therapy*
D000970:Antineoplastic Agents; D007155:Immunologic Factors